ADVA brings ultra-precise timing to open servers with new PTP solution
9.5.2022 14:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched OSA SoftSync™ to help network operators and enterprises deliver robust and highly precise network timing as a software application. The new solution offers a straightforward and cost-effective way to add ADVA’s Oscilloquartz Precision Time Protocol (PTP) capabilities to open servers and network devices. Now customers can easily migrate to precise and resilient packet timing that can run on any Linux machine. OSA SoftSync™ will be key to meeting more stringent timing requirements in a wide range of industries, including 5G, financial trading, cloud computing and globally dispersed data centers.
“A key step in the digitization of IT systems and enterprises is the transition from NTP to PTP timing. Our OSA SoftSync™ makes that possible by filling in the synchronization gap at the edge of the network. At the click of a button, it gives operators the power of highly accurate PTP timestamping,” said Gil Biran, GM of Oscilloquartz, ADVA. “An entirely new set of customers can now harness the benefits of our extensive and proven synchronization portfolio without hassle or major investment. Whether it’s 5G O-RAN or advanced data center applications, our software solution opens up new possibilities for network operators across many different fields.”
OSA SoftSync™ is an easily deployable software PTP client able to deliver ultra-precise and robust time for server-hosted applications. It utilizes ADVA Oscilloquartz PTP technology, clock recovery algorithms, and Syncjack™ performance monitoring and assurance capabilities. Ready to be installed on any Linux distribution, OSA SoftSync™ features multiple management options, including telemetry streaming, a modern and user-friendly GUI and ADVA’s Ensemble Sync Director. OSA SoftSync™ can utilize NIC hardware-based timestamping to achieve nanosecond level accuracy. It mitigates timing source outages or loss of quality by dynamically selecting the most accurate synchronization source based on the best master clock algorithm. Customers can purchase OSA SoftSync™ through a simple annual subscription model.
“Applications running on open servers require timing with new levels of accuracy and resilience. Today’s current raft of software clocks are simply not up to the sync challenges of new use cases. Our OSA SoftSync™ is the answer. For a low total cost of ownership, it creates an end-to-end synchronization architecture able to meet the needs of advanced time-critical services. What’s more, OSA SoftSync™ is fully interoperable with a wide range of PTP grandmasters,” commented Nir Laufer, VP of product line management at Oscilloquartz, ADVA. “From data centers to financial institutions, customers can now address industry regulations, including MiFID II and CAT NMS, and meet the demands of next-generation applications without the risk of major investment.”
More information on OSA SoftSync™ is available in these slides: https://adva.li/osa-softsync-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005413/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis4.8.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the inflammatory mechanisms underlying both symptoms and disease progression in knee osteoarthritis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803530661/en/ 4Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis as a driver of pain and disease progression in knee osteoarthritis INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial conducted across Europe, the United States and Canada
ClickHouse Launches ClickHouse Labs With Andy Pavlo as VP of Database Research3.8.2026 16:30:00 EEST | Press release
ClickHouse today announced the launch of ClickHouse Labs, a new research group led by Andy Pavlo, one of the database industry’s most prominent researchers. Dr. Pavlo joins ClickHouse as Vice President of Database Research and will build a team dedicated to advancing the state of the art in database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803890510/en/ Andy Pavlo, VP of Database Research, ClickHouse Pavlo is an award-winning database researcher and professor at Carnegie Mellon University’s Computer Science Department. He is known throughout the database community for his work on autonomous databases, transaction processing, and large-scale data analytics. At ClickHouse, he will bring that expertise to some of the most ambitious and consequential challenges facing modern data systems, as AI reshapes the demands placed on all data-intensive workloads. “At ClickHouse, we are interested in finding new and inno
Lehman Brothers Treasury Considers Sale and Final Wind-Down3.8.2026 16:30:00 EEST | Press release
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining asset – a $19.6 billion Class 4A allowed claim against Lehman Brothers Holdings Inc. (the “LBHI Claim”). LBT expects the sale to occur, if at all, in August 2026. To the extent the LBHI Claim is sold, LBT expects to make a final distribution to the holders of its existing notes and thereafter facilitate the cancellation of those notes and the final wind down of its estate in September 2026. The foregoing is subject to further consents and authorizations and LBT retains sole discretion to abandon or otherwise discontinue any sale process at any time. Accordingly, there can be no assurances that the sale process will be conducte
EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership3.8.2026 16:00:00 EEST | Press release
EuroTeleSites, one of Central and Eastern Europe's leading independent tower companies, today announced the results of its first year in partnership with Sitetracker, the leading global Asset Lifecycle Management platform. One year into the deployment, EuroTeleSites reports meaningful progress in its digital transformation, with measurable improvements in operational efficiency, cross-market transparency, and project coordination across its six-country footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727009809/en/ EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership Driving Efficiency in a Complex, High-Investment Environment EuroTeleSites invests approximately 25% of its revenue into capital expenditures in 2026, funding the construction and upgrade of tower infrastructure across Central and Eastern European markets. Managing this level of scale and complexity demands robust digital support
Visa to Acquire BioCatch3.8.2026 15:30:00 EEST | Press release
Visa (NYSE: V) today announced it has signed a definitive agreement to acquire BioCatch, a leading provider of behavioral-first, multi-signal fraud intelligence, from funds advised by Permira and other shareholders for $2.4 billion in cash. The acquisition of BioCatch complements Visa’s existing cyber, fraud, risk and security solutions and is expected to help clients better protect themselves and their customers from the growing threat of account takeovers, scams, money mules and application fraud. Since its inception, BioCatch has developed innovative AI and machine learning-based solutions that analyze thousands of application, behavioral, device, and network signals—such as keystrokes, touch gestures, and device handling—to detect fraud and distinguish legitimate users from fraudsters in real time. BioCatch protects 1.8 billion devices and 760 million users around the world, serving more than 350 banking clients in 21 different countries, including more than 100 of the largest bank
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom